---
schema_version: "secwatch.filing_event.v1"
accession: "0000719135-22-000030"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T19:38:47.272633+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q1 revenue up 45% to $12.5M, net loss widens, guidance narrowed

## Summary
- Revenue $12.5M (+45% YoY); Advanced Energy $10.8M (+41%), OEM $1.7M (+72%).
- Net loss attributable to stockholders $5.9M ($0.17/share) vs $4.9M ($0.14) prior year.
- Adjusted EBITDA loss $4.0M vs $3.4M; operating expenses rose 33% to $14.1M.
- FY2022 revenue guidance narrowed to $52.5-59.0M (prior $50-63M); Advanced Energy $46-52M (prior $43.5-56M).
- FDA Safety Communication in March impacted U.S. new customer adoption; 510(k) submissions for dermal/laxity pending.

## SEC filing metadata
- accession: 0000719135-22-000030
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000071913522000030/0000719135-22-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000071913522000030/apyx-20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000719135-22-000030
- JSON: https://secwatch.observer/filing/0000719135-22-000030.json
- Plain text: https://secwatch.observer/filing/0000719135-22-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.